

Název: **Molecular biology of influenza virus**

Školitel: **Ludmila Krejčová**

Datum: **31. 10. 2014**

Reg.č.projektu: CZ.1.07/2.3.00/20.0148


Název projektu: Mezinárodní spolupráce v oblasti "in vivo" zobrazovacích technik



Basics about Influenza



Symptoms of Influenza



- An **infectious respiratory disease** of birds and mammals
- Transmitted by **droplet infection**
- **Incubation period 12-72 h**
- sneezing, coughing, fever, headache....

- **ss (-) RNA viruses, family Orthomyxoviridae**

- Three genera: Influenza A, B and C


(difference in structure, host range and virulence)

type A: most virulent, cause epidemic and pandemic

type B: cause epidemics only in human population

type C: causes disease exceptionally

Structure of influenza virus




- **80-120 nm, spherical**
(filamentous forms can occur – type C)
- Envelope, surface structure (two antigens), core
Genom: ss RNA is **segmented** (7 or 8 segments)
- Each segment encoded one or two proteins
- **11 proteins** (influenza A+B):

haemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), M1, M2, PA, PB1, PB1-F2, PB2, NS1 and NS2 (non structural proteins)


Surface antigens



- HA and NA are the two large glycoproteins
- **HA** (trimer) – **entry of virus into host cell**
- **NA** (tetramer) – **release of new formed virions** (after replication)
- Subtyping of influenza type A
 - based on combinations of different variants of HA(1-17) and NA(1-9)
- **In human population are common H1, H2, H3 and N1, N2**



Life cycle of influenza viruses



- Viruses can replicate only in living cells
- **HA** (virus) bind **sialic acid receptor** (host cell)
- HA is cleaved by a protease (lung surfactant)
- Import of the virus by **endocytosis**
- Enter the target **endosomes** for genome release
- **Release the viral RNA** and core proteins
- **Replication, transcription** (and splicing), **translation**
- Formation of **HA** and **NA** on **surface of host cell**
- Formation of core (**vRNA**) and **envelope**
- **NA** lyse bond between HA and sialic acid
- **Release of new formed virions** after replication

Preventive measures and therapy



Vaccine

- Only **one way to control** of influenza
- Vaccine is useable only one year (due to mutational changes)
- Each year two new vaccines (Northern and Southern hemisphere)
- In collaboration with **WHO** and **Centers for Disease Control and Prevention**
- Predict which strains will circulate in the next year

Therapy

- **Antibiotics** - only for therapy of secondary infection (bacterial pneumonia)
- **Antivirals** - neuraminidase inhibitors (NI) (Zanamivir, Oseltamivir)
 - M2 blockers (amantadine and Rimantidine)

NI - effective against influenza **A and B**

- different strains / different resistance
- new formed virions are incapable for release of new formed virion)

M2 blockers - block a viral ion channel (M2) and prevent the virus from infecting cells

- effective against influenza **A not B**
- currently **increasing resistance** (H3N2 80%)







Financial support from the projects **Nanolabsys**
CZ.1.07/2.3.00/20.0148 is gratefully acknowledged.



- All colleagues from Laboratory of Metallomics and nanotechnology



Děkuji za pozornost!



MINISTERSTVO ŠKOLSTVÍ,
MLÁDEŽE A TĚLOVÝCHOVY



OP Vzdělávání
pro konkurenceschopnost

INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ

Mendel
University
in Brno

